Payment overview · 2025
General Payments
$1,193.87
48 reported records · 11 companies
Healthcare provider profile · identity verified
George W Mathews, DO
Allopathic & Osteopathic Physicians|Family Medicine · HUMANSVILLE, MO · NPI 1619980919
Verified facts
What the public records show
CMS Open Payments records show George W Mathews, DO received $1,193.87 in general payments during 2025 across 48 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Ingrezza, Mounjaro, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Myrbetriq by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Caplyta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $506.32 | 42.4% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $160.58 | 13.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $134.99 | 11.3% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $124.99 | 10.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $85.03 | 7.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.53 | 4.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.70 | 4.2% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $25.83 | 2.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.98 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.55 | 1.3% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $14.37 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,193.87 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $315.78 | 16 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $190.54 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.21 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $134.99 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $85.03 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.70 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 91 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
209 | 15 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
138 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
91 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 808 | 90 |
| Atorvastatin Calcium | Atorvastatin Calcium | 708 | 91 |
| Gabapentin | Gabapentin | 614 | 84 |
| Furosemide | Furosemide | 541 | 83 |
| Divalproex Sodium | Divalproex Sodium | 507 | 62 |
| Lisinopril | Lisinopril | 492 | 65 |
| Potassium Chloride | Potassium Chloride | 477 | 66 |
| Eliquis | Apixaban | 473 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 472 | 65 |
| Trazodone Hcl | Trazodone Hcl | 422 | 57 |
| Sertraline Hcl | Sertraline Hcl | 414 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 321 | 46 |
| Lorazepam | Lorazepam | 315 | 74 |
| Escitalopram Oxalate | Escitalopram Oxalate | 306 | 42 |
| Mirtazapine | Mirtazapine | 305 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 294 | 39 |
| Buspirone Hcl | Buspirone Hcl | 289 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 274 | 41 |
| Risperidone | Risperidone | 265 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 255 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 255 | 44 |
| Metformin Hcl | Metformin Hcl | 239 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 33 |
| Myrbetriq | Mirabegron | 209 | 15 |
| Tramadol Hcl | Tramadol Hcl | 205 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 199 | 25 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 180 | 13 |
| Omeprazole | Omeprazole | 177 | 27 |
| Olanzapine | Olanzapine | 158 | 18 |
| Topiramate | Topiramate | 158 | 26 |
| Aripiprazole | Aripiprazole | 156 | 26 |
| Carvedilol | Carvedilol | 146 | 24 |
| Xarelto | Rivaroxaban | 145 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 138 | suppressed |
| Finasteride | Finasteride | 137 | 17 |
| Baclofen | Baclofen | 134 | 17 |
| Memantine Hcl | Memantine Hcl | 134 | 20 |
| Losartan Potassium | Losartan Potassium | 132 | 21 |
| Clonazepam | Clonazepam | 131 | 12 |
| Pregabalin | Pregabalin | 126 | 15 |
| Spironolactone | Spironolactone | 125 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 124 | 12 |
| Prednisone | Prednisone | 118 | 30 |
| Invega Sustenna | Paliperidone Palmitate | 112 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 105 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 100 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 15 |
| Ozempic | Semaglutide | 96 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 95 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 95 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 95 | 28 |
| Alendronate Sodium | Alendronate Sodium | 93 | suppressed |
| Clozapine | Clozapine | 93 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 93 | suppressed |
| Rexulti | Brexpiprazole | 91 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 90 | suppressed |
| Nystatin | Nystatin | 89 | 39 |
| Donepezil Hcl | Donepezil Hcl | 86 | 14 |
| Meloxicam | Meloxicam | 86 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 85 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 83 | 12 |
| Simvastatin | Simvastatin | 83 | 11 |
| Jardiance | Empagliflozin | 82 | suppressed |
| Januvia | Sitagliptin Phosphate | 81 | suppressed |
| Vraylar | Cariprazine Hcl | 81 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 73 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 20 |
| Fentanyl | Fentanyl | 73 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 24 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 71 | 13 |
| Bumetanide | Bumetanide | 71 | 14 |
| Levetiracetam | Levetiracetam | 71 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 71 | suppressed |
| Metolazone | Metolazone | 68 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 11 |
| Amantadine | Amantadine Hcl | 66 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 65 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | suppressed |
| Haloperidol | Haloperidol | 64 | 13 |
| Enulose | Lactulose | 61 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 12 |
| Ceftriaxone | Ceftriaxone Sodium | 59 | 37 |
| Primidone | Primidone | 59 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 57 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 55 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | 11 |
| Allopurinol | Allopurinol | 53 | suppressed |
| Digoxin | Digoxin | 53 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 15 |
| Ingrezza | Valbenazine Tosylate | 53 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 53 | 15 |
| Lidocaine Hcl | Lidocaine Hcl | 52 | 31 |
| Prazosin Hcl | Prazosin Hcl | 52 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 50 | suppressed |
| Cefdinir | Cefdinir | 48 | 25 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 12 |
| Aptiom | Eslicarbazepine Acetate | 47 | suppressed |
| Briviact | Brivaracetam | 46 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | suppressed |
| Temazepam | Temazepam | 46 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Trulicity | Dulaglutide | 45 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 43 | 18 |
| Albuterol Sulfate | Albuterol Sulfate | 42 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 37 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 14 |
| Klor-Con M20 | Potassium Chloride | 35 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Ertapenem | Ertapenem Sodium | 33 | 20 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 16 |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 33 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 20 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | 13 |
| Ondansetron Odt | Ondansetron | 31 | 22 |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 30 | suppressed |
| Caplyta | Lumateperone Tosylate | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Fiasp Penfill | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Paliperidone Er | Paliperidone | 23 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Movantik | Naloxegol Oxalate | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 21 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Isentress | Raltegravir Potassium | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Atenolol | Atenolol | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 18 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Nystop | Nystatin | 18 | 11 |
| Thiothixene | Thiothixene | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Letrozole | Letrozole | 17 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | 13 |
| Methimazole | Methimazole | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Abilify Maintena | Aripiprazole | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Santyl | Collagenase Clostridium Hist. | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,193.87 · 48 records | Teva Pharmaceuticals USA, Inc. | ARISTADA, AUSTEDO XR, CAPLYTA, INGREZZA, KISUNLA, LYBALVI, MOUNJARO, Ozempic, REXULTI, Rybelsus, SKYCLARYS, UZEDY, VRAYLAR, Veozah, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error